

Massimo Bernardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3034035/publications.pdf>

Version: 2024-02-01

86
papers

5,362
citations

126907

33
h-index

85541

71
g-index

87
all docs

87
docs citations

87
times ranked

6248
citing authors

#	ARTICLE	IF	CITATIONS
1	Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation. <i>Blood Advances</i> , 2022, 6, 3053-3057.	5.2	7
2	Allogeneic hematopoietic stem cell transplantation in patients older than 65 years with acute myeloid leukemia and myelodysplastic syndrome: a 15-year experience. <i>Bone Marrow Transplantation</i> , 2022, 57, 678-680.	2.4	4
3	Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol. <i>Cancers</i> , 2022, 14, 3012.	3.7	0
4	Microbiome markers are early predictors of acute GVHD in allogeneic hematopoietic stem cell transplant recipients. <i>Blood</i> , 2021, 137, 1556-1559.	1.4	18
5	Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL). <i>Journal of Geriatric Oncology</i> , 2021, 12, 550-556.	1.0	12
6	MATRIX-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e110-e121.	4.6	54
7	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 1223-1233.	1.6	127
8	The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106335.	2.5	9
9	Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia. <i>Nature Communications</i> , 2021, 12, 4844.	12.8	3
10	Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial. <i>Frontiers in Oncology</i> , 2021, 11, 731478.	2.8	8
11	Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. <i>Blood Advances</i> , 2021, 5, 4370-4379.	5.2	5
12	Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 776.e1-776.e13.	1.2	26
13	Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience. <i>Leukemia Research</i> , 2021, 109, 106642.	0.8	8
14	Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. <i>Haematologica</i> , 2021, 106, 2578-2587.	3.5	15
15	Coadministration of letermovir and sirolimus in allogeneic hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2021, , .	2.4	1
16	Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07. <i>Blood Cancer Journal</i> , 2020, 10, 119.	6.2	29
17	SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. <i>HemaSphere</i> , 2020, 4, e483.	2.7	7
18	Infections after Allogeneic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1179-1188.	2.0	49

#	ARTICLE	IF	CITATIONS
19	Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy. <i>Hematological Oncology</i> , 2019, 37, 447-455.	1.7	25
20	Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide. <i>Frontiers in Immunology</i> , 2019, 10, 2319.	4.8	25
21	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. <i>Nature Medicine</i> , 2019, 25, 603-611.	30.7	253
22	Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. <i>Blood Advances</i> , 2019, 3, 1103-1117.	5.2	23
23	Nanosphere's Verigene® Blood Culture Assay to Detect Multidrug-Resistant Gram-Negative Bacterial Outbreak: A Prospective Study on 79 Hematological Patients in a Country with High Prevalence of Antimicrobial Resistance. <i>Clinical Hematology International</i> , 2019, 1, 120-123.	1.7	2
24	Clinical Impact of Pretransplant Multidrug-Resistant Gram-Negative Colonization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1476-1482.	2.0	39
25	Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients. <i>Bone Marrow Transplantation</i> , 2018, 53, 410-416.	2.4	10
26	Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL). <i>American Journal of Hematology</i> , 2018, 93, E54-E57.	4.1	1
27	Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. <i>American Journal of Hematology</i> , 2018, 93, 1236-1244.	4.1	40
28	Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network. <i>Annals of Hematology</i> , 2018, 97, 2107-2115.	1.8	2
29	Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. <i>American Journal of Hematology</i> , 2017, 92, 1011-1019.	4.1	14
30	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. <i>Leukemia</i> , 2017, 31, 2449-2457.	7.2	51
31	Clinical management of peripherally inserted central catheters compared to conventional central venous catheters in patients with hematological malignancies: A large multicenter study of the <sc>REL</sc> <sc>GROUP</sc> (Rete Ematologica Lombarda - Lombardy Hematologic Network,). <i>Tj ETQq1 10.78431419gBT /O</i>	4.1	19
32	A New Clinicobiological Scoring System for the Prediction of Infection-Related Mortality and Survival after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2151-2158.	2.0	9
33	Control of infectious mortality due to carbapenemase-producing <i>Klebsiella pneumoniae</i> in hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 114-119.	2.4	33
34	Enteric Microbiome Markers as Early Predictors of Clinical Outcome in Allogeneic Hematopoietic Stem Cell Transplant: Results of a Prospective Study in Adult Patients. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx215.	0.9	45
35	Elderly patients >65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programs. <i>American Journal of Hematology</i> , 2016, 91, E302-3.	4.1	2
36	Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2016, 101, e157-e161.	3.5	55

#	ARTICLE	IF	CITATIONS
37	Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2016, 51, 1022-1024.	2.4	6
38	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 3627-3637.	1.6	204
39	Human Herpesvirus 6 Infection Following Haploidentical Transplantation: Immune Recovery and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2250-2255.	2.0	36
40	Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. <i>Blood</i> , 2016, 128, 1528-1531.	1.4	46
41	Integrating a prospective pilot trial and patient-derived xenografts to trace metabolic changes associated with acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2016, 9, 115.	17.0	4
42	Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. <i>Hematological Oncology</i> , 2016, 34, 154-160.	1.7	6
43	Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse. <i>Bone Marrow Transplantation</i> , 2016, 51, 466-469.	2.4	6
44	The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the Rete Ematologica Lombarda. <i>Leukemia Research</i> , 2016, 42, 21-27.	0.8	7
45	High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2016, 96, 629-636.	2.2	35
46	Postremission intensive treatment after induction chemotherapy is feasible in selected elderly patients with acute myeloid leukemia and age ≥75 years: A retrospective analysis of the Rete Ematologica Lombarda. <i>American Journal of Hematology</i> , 2015, 90, E123-5.	4.1	2
47	Haploidentical HSCT: a 15-year experience at San Raffaele. <i>Bone Marrow Transplantation</i> , 2015, 50, S67-S71.	2.4	6
48	Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1506-1514.	2.0	121
49	Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. <i>Leukemia</i> , 2015, 29, 396-405.	7.2	114
50	Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. <i>Leukemia</i> , 2015, 29, 1143-1152.	7.2	110
51	Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall. <i>Bone Marrow Transplantation</i> , 2015, 50, 1262-1264.	2.4	11
52	Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells. <i>Frontiers in Immunology</i> , 2014, 5, 16.	4.8	126
53	Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. <i>Annals of Neurology</i> , 2014, 75, 447-453.	5.3	43
54	Wilms' Tumor Gene 1 Transcript Levels in Leukapheresis of Peripheral Blood Hematopoietic Cells Predict Relapse Risk in Patients Autografted for Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1586-1591.	2.0	26

#	ARTICLE	IF	CITATIONS
55	Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. <i>Blood</i> , 2014, 123, 2333-2342.	1.4	162
56	Autologous Pancreatic Islet Transplantation in Human Bone Marrow. <i>Diabetes</i> 2013;62:3523-3531. <i>Diabetes</i> , 2014, 63, 377-377.	0.6	0
57	Validating the Patient's "Fitness" Criteria Proposed to Guide Treatment Decision in Elderly AML: a Multicenter Study on a Population-Based Series of 362 Patients By the Network "Rete Ematologica Lombarda" (REL). <i>Blood</i> , 2014, 124, 279-279.	1.4	2
58	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 581-588.	4.1	61
59	Autologous Pancreatic Islet Transplantation in Human Bone Marrow. <i>Diabetes</i> , 2013, 62, 3523-3531.	0.6	90
60	Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: The experience of the "Rete Ematologica Lombarda". <i>Leukemia Research</i> , 2013, 37, 1233-1240.	0.8	20
61	Graft-versus-leukemia Effect of HLA-haploidentical Central-memory T-cells Expanded With Leukemic APCs and Modified With a Suicide Gene. <i>Molecular Therapy</i> , 2013, 21, 466-475.	8.2	23
62	CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. <i>Blood</i> , 2013, 122, 3461-3472.	1.4	306
63	Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of transplant. <i>Leukemia and Lymphoma</i> , 2012, 53, 96-102.	1.3	24
64	Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Who Classification-Based Prognostic Scoring System (WPSS). <i>Blood</i> , 2011, 118, 116-116.	1.4	1
65	Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. <i>Haematologica</i> , 2010, 95, 476-484.	3.5	144
66	Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. <i>Bone Marrow Transplantation</i> , 2009, 44, 237-242.	2.4	18
67	Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). <i>Blood</i> , 2009, 113, 4153-4162.	1.4	387
68	Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2009, 361, 478-488.	27.0	459
69	Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase II study. <i>Lancet Oncology</i> , 2009, 10, 489-500.	10.7	458
70	Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donors. <i>Leukemia</i> , 2008, 22, 2119-2122.	7.2	12
71	M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. <i>Haematologica</i> , 2008, 93, 1025-1032.	3.5	18
72	Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2008, 49, 727-733.	1.3	27

#	ARTICLE	IF	CITATIONS
73	Temporal, quantitative, and functional characteristics of single-KIR ⁺ positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. <i>Blood</i> , 2008, 112, 3488-3499.	1.4	113
74	WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Blood</i> , 2008, 112, 895-902.	1.4	192
75	Antitumor effects of HSV-TK ⁺ engineered donor lymphocytes after allogeneic stem-cell transplantation. <i>Blood</i> , 2007, 109, 4698-4707.	1.4	171
76	Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer. <i>Bone Marrow Transplantation</i> , 2006, 37, 311-315.	2.4	2
77	Rapamycin Induces a Caspase-Independent Cell Death in Human Monocytes. <i>American Journal of Transplantation</i> , 2006, 6, 1331-1341.	4.7	23
78	MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. <i>Neurology</i> , 2006, 66, 1435-1438.	1.1	83
79	Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 1457-1462.	7.1	172
80	Rapid and Wide Immunoreconstitution Obtained with HSV-TK Engineered Donor Lymphocyte Add-Backs Permits Long-Term Survival after haplo-HSCT. <i>Blood</i> , 2006, 108, 307-307.	1.4	4
81	Allogeneic stem cell transplantation for the treatment of advanced solid tumors. <i>Seminars in Immunopathology</i> , 2004, 26, 95-108.	4.0	18
82	Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. <i>Blood</i> , 2002, 99, 4234-4236.	1.4	209
83	Combined Treatment with High-Dose Methotrexate, Vincristine and Procarbazine, without Intrathecal Chemotherapy, Followed by Consolidation Radiotherapy for Primary Central Nervous System Lymphoma in Immunocompetent Patients. <i>Oncology</i> , 2001, 60, 134-140.	1.9	82
84	Locoregional intrasplenic chemotherapy for hypersplenism in myelofibrosis. <i>British Journal of Haematology</i> , 2001, 114, 638-640.	2.5	2
85	Mono-oligoclonal immunoglobulin abnormalities in diabetic patients after kidney transplantation: influence of simultaneous pancreas graft. <i>Diabetologia</i> , 1998, 41, 1176-1179.	6.3	3
86	Transfer of the HSV-tk Gene into Donor Peripheral Blood Lymphocytes for In Vivo Modulation of Donor Anti-Tumor Immunity after Allogeneic Bone Marrow Transplantation. The San Raffaele Hospital, Milan, Italy. <i>Human Gene Therapy</i> , 1995, 6, 813-819.	2.7	137